Orchid Pharma has entered into a licensing agreement for one of its antibiotic products in Russia, marking another step in its international expansion strategy. The agreement is expected to strengthen the company’s overseas presence and improve export opportunities.
The company continues focusing on specialty pharmaceuticals and regulated markets while investing in research and product development. Investors believe international partnerships could contribute to sustained long-term growth.
